Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Subacute (acute, persistent) thrombotic microangiopathy.

E G Taft, B B Carver

    Journal of Clinical Apheresis
    |January 1, 1992
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Clinical experience with a notebook PC.

    M.D. computing : computers in medical practice·1994
    Same author

    Advances in the treatment of TTP.

    Progress in clinical and biological research·1990
    Same author

    Therapeutic apheresis.

    Human pathology·1983
    Same author

    Leukapheresis in acute leukemia--is it necessary?

    Progress in clinical and biological research·1982
    Same author

    Plasma exchange transfusion.

    Seminars in thrombosis and hemostasis·1981
    Same author

    Management of thrombocytosis.

    Transfusion·1980

    This study reviews patients with prolonged thrombotic microangiopathy requiring extensive plasma support for over three months, achieving complete remission. This distinct subset of thrombotic microangiopathy differs from typical acute courses.

    Area of Science:

    • Hematology
    • Internal Medicine
    • Pathology

    Background:

    • Thrombotic microangiopathy (TMA) encompasses disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ damage.
    • Typical acute courses of thrombotic thrombocytopenic purpura (TTP) resolve within 3-6 weeks.
    • Chronic relapsing TMA patterns can present with variable acute phases.

    Purpose of the Study:

    • To describe a distinct subset of thrombotic microangiopathy with prolonged acute disease courses.
    • To characterize the treatment requirements and outcomes of these patients.

    Main Methods:

    • Retrospective review of six patients with thrombotic microangiopathy.
    • Analysis of disease duration, plasma support requirements, and remission status.

    Related Experiment Videos

    Main Results:

    • All six patients experienced prolonged acute courses requiring plasma support exceeding three months.
    • Prodigious plasma support was necessary, with some patients undergoing over 100 plasma exchanges.
    • All patients achieved complete remission following intensive treatment.

    Conclusions:

    • A distinct subset of thrombotic microangiopathy characterized by prolonged acute phases exists.
    • These patients require extensive plasma support for extended periods, differentiating them from typical TTP presentations.
    • Complete remission is achievable in this subset with intensive management.